Accounts Receivable
Vertex Pharmaceuticals Accounts Receivable decreased by 2.8% to $2B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 10.6%, from $1.81B to $2B. Over 5 years (FY 2020 to FY 2025), Accounts Receivable shows an upward trend with a 18.3% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Analysis
How to read this metric
A rising balance relative to revenue may signal collection issues or aggressive credit terms, while a stable balance indicates efficient cash conversion.
Detailed definition
This represents the balance of money owed to the company by customers for goods or services delivered, adjusted for an a...
Peer comparison
Standard across pharmaceutical companies based on distribution agreements with wholesalers and pharmacy benefit managers.
accounts_receivable_netHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $929.14M | $1.1B | $1.14B | $1.29B | $1.33B | $1.39B | $1.44B | $1.55B | $1.56B | $1.54B | $1.56B | $1.79B | $1.66B | $1.75B | $1.61B | $1.81B | $1.89B | $1.95B | $2.05B | $2B |
| QoQ Change | — | +18.4% | +3.3% | +13.7% | +3.1% | +3.9% | +4.1% | +7.3% | +0.5% | -1.1% | +1.6% | +14.7% | -7.6% | +5.7% | -8.1% | +12.2% | +4.9% | +2.8% | +5.5% | -2.8% |
| YoY Change | — | — | — | — | +43.5% | +25.9% | +26.9% | +19.7% | +16.8% | +11.1% | +8.4% | +15.9% | +6.4% | +13.8% | +2.9% | +0.7% | +14.3% | +11.2% | +27.6% | +10.6% |
Accounts Receivable at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's accounts receivable?
- Vertex Pharmaceuticals (VRTX) reported accounts receivable of $2B in Q1 2026.
- How has Vertex Pharmaceuticals's accounts receivable changed year-over-year?
- Vertex Pharmaceuticals's accounts receivable increased by 10.6% year-over-year, from $1.81B to $2B.
- What is the long-term trend for Vertex Pharmaceuticals's accounts receivable?
- Over 5 years (2020 to 2025), Vertex Pharmaceuticals's accounts receivable has grown at a 18.3% compound annual growth rate (CAGR), from $885.4M to $2.05B.
- What does accounts receivable mean?
- The net amount of money customers owe the company for products already delivered.